David Bredt - Chief Scientific Officer at Rapport Therapeutics, Inc.

Insider Transactions and Holdings

Entity Type
Individual
Role
Chief Scientific Officer
Issuer Symbol
RAPP on Nasdaq
All Insider Reports
All Insider Reports

David Bredt - trading volume in the past year for Rapport Therapeutics, Inc.

Holdings reported by David Bredt for Rapport Therapeutics, Inc.

Security Num Shares Value Price $ Transaction Date Ownership Underlying Class Underlying Amount
Common Stock 395,575 $10,838,755 $27.40 15 Jan 2026 Direct
Stock Option (Right to Buy) 103,000 02 Feb 2026 Direct Common Stock

Transactions reported by David Bredt for Rapport Therapeutics, Inc.

Sym Class Transaction % Value $ * Price $ Shares Shares After Date Ownership
* An asterisk sign (*) next to the price indicates that the price is likely invalid.